TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT

Capital Medical University

Status and phase

Unknown

Phase 4

Conditions

Acute Ischemic Stroke

Treatments

Combination Product: Urapidil Hydrochloride Injection

Study type

Interventional

Funder types

Other

Identifiers

NCT03529149

[2018]007

Details and patient eligibility

About

Investigators hypothesized that the precise regulation of blood pressure based on the changes of cerebral blood flow parameters under TCD monitoring can better improve the state of cerebral blood flow, reduce the risk of early neurological deterioration and improve the prognosis of the patients.

Enrollment

90 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 years of age or older;
accept EVT treatment within 6 hours of symptoms onset;
In selected patients with AIS within 6 to 16 hours of last known normal who have LVO in the anterior circulation and meet other DAWN or DEFUSE 3 eligibility criteria..
In selected patients with AIS within 6 to 24 hours of last known normal who have LVO in the anterior circulation and meet other DAWN eligibility criteria.

Exclusion criteria

Pre - onset mRS>2;
severe dementia;
threatening life diseases (such as malignant tumor, etc.);
non acute ischemic cerebrovascular disease patients undergoing selective intravascular treatment;
related sound window closure can not be monitoring with TCD.